Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
A phase 3 trial testing Lerotinib in oesophageal cancer, now recruiting.
Overview
Study of Larotinib in Unresectable Advanced or Recurrent Oesophageal Cancer is a phase 3 interventional study registered as NCT04415853, led by Sunshine Lake Pharma, and recruiting when checked on 2026-09-11. Official title: Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Oesophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study. Planned enrolment is 416 participants (estimated). The study started in 2021-01-21 and primary completion is expected in 2026-08. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Shares Oesophageal cancer and the tag ctgov-ingest.
- TrialQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shares Oesophageal cancer and the tag ctgov-ingest.
- TrialSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Shares Oesophageal cancer and the tag ctgov-ingest.
- TreatmentTQB6411
Shares Oesophageal cancer and the tag ctgov-ingest.
- TreatmentAZD5863
Shares Oesophageal cancer and the tag ctgov-ingest.
- TreatmentKC1036
Shares Oesophageal cancer and the tag ctgov-ingest.
- TreatmentHMBD-001
Shares Oesophageal cancer and the tag ctgov-ingest.
- TreatmentHLX43
Shares Oesophageal cancer and the tag ctgov-ingest.